Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank)
Refrigeration recommended after reconstitution
Vanhee C, et al
Onco Targets Ther
Nationwide: FDA removes 12 peptides from Category 2, but they're not cleared Key facts: On April 22, 2026, the FDA removed 12 peptides from Category 2 of its 503A bulk drug substances list
It is still not FDA-approved and still carries uncertainty, but it exists within a medical and pharmacy framework
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
